News >

Expert Highlights Advances in Cutaneous T-Cell Lymphoma

Angelica Welch
Published: Thursday, Jan 18, 2018

Wei Z. Ai, MD

Wei Z. Ai, MD
Cutaneous T-cell lymphoma (CTCL) is known to be a rare malignancy, with approximately 3000 diagnoses per year. Historically, progress in developing therapies for this form of non-Hodgkin lymphoma (NHL) has been slow, but 2017 brought about the FDA approval of brentuximab vedotin (Adcetris), giving hope to this poor-prognosis population.

Wei Z. Ai, MD, an associate clinical professor and hematologist at the University of California, San Francisco (UCSF) Medical Center, gave a presentation on recent developments in T-cell lymphoma during the 2017 OncLive® State of the Science SummitTM on Hematologic Malignancies. In an interview during the meeting, Ai discussed the impact of brentuximab vedotin, as well as the potential with mogamulizumab in CTCL.

OncLive: What recent data have we seen in this space?

Ai: In systemic T-cell lymphoma, there were no practice-changing trials presented [at the 2017 ASH Annual Meeting]. However, we are hoping for results from some exciting phase I/II trials in 2018. Phase III trials based on those trials are ongoing, and may be practice changing.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication